Advanced Search
GUO Qiuyun, YU Shiying. Comparison of Lorazepam,Diphenhydramine,Haloperidol Combined with Tropisetron and Dexamethasone Combined with Tropisetron Efficacy in Preventing Emesis Induced by Highly Emetogenic Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 798-800. DOI: 10.3971/j.issn.1000-8578.2013.08.017
Citation: GUO Qiuyun, YU Shiying. Comparison of Lorazepam,Diphenhydramine,Haloperidol Combined with Tropisetron and Dexamethasone Combined with Tropisetron Efficacy in Preventing Emesis Induced by Highly Emetogenic Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 798-800. DOI: 10.3971/j.issn.1000-8578.2013.08.017

Comparison of Lorazepam,Diphenhydramine,Haloperidol Combined with Tropisetron and Dexamethasone Combined with Tropisetron Efficacy in Preventing Emesis Induced by Highly Emetogenic Chemotherapy

More Information
  • Received Date: August 05, 2012
  • Revised Date: November 12, 2012
  • Objective To compare the efficacy of lorazepam, diphenhydramine and haloperidol(abbreviation as ABH)combined with Tropisetron therapies in preventing emesis induced by highly emetogenic chemotherapy refer to 2011 edition of MASCC antiemetic guidelines. Methods One hundred and four patients treated with highly emetogenic single day chemotherapy were randomized into ABH and dexamethasone group. Both groups were given tropisetron 5mg intravenous infusion 30 minutes before chemical therapy. Patients in group ABH took lorazepam 0.34 mg, diphenhydramine 25 mg, haloperidol 1.5mg orally thrice a day on the therapy day and three days later. Group dexamethasone was given dexamethasone 20 mg once on the therapy day and 8 mg twice three days later. To study the control rate of acute,delayed nausea and vomiting and the patient's living quality,we used the MASCC antiemetic questionnaires and the functional living index-Emesis questionnaire. Results Fifty two patients were enrolled into each group. Both groups had a good control of acute,delayed nausea and vomiting.The control rates of acute nausea in Group ABH and Group dexamethasone were 62% vs.52%,77% vs. 65% in delayed nausea,and 88% vs. 87% in acute vomiting,77%vs. 65% in delayed vomiting.Group ABH was better than group dexamethasone, but there was no statistical difference between them,which may be caused by the small sample sizes. It's worth mentioning that Group ABH was superior to Group dexamethasone in the control of delayed nausea degree(2.63 vs. 3.69)(P<0.05). The patient's living quality was moderately influenced but there was no statistical difference and serious side effects in both groups. Conclusion Lorazepam, diphenhydramine and haloperidol (ABH)combined with 5HT-3 receptor antagonist therapy has a good effect in preventing emesis induced by highly emetogenic chemotherapy, with little side effects, and can be to trent chemotherapy induced nausea and vomiting (CINV).
  • [1]
    Decker GM, DeMeyer ES, Kisko DL.Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy[J].J Support Oncol,2006 ,4(1):35-41, 52.
    [2]
    Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach[J]. Support Care Cancer, 2002,10(7):519-22.
    [3]
    Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control[J]. Oncologist,2003,8(2):187-98.
    [4]
    Jordan K, Kasper C,Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment[J]. Eur J Cancer,2005,41(2):199-205.
    [5]
    Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)[J].Ann Oncol,2012,23(8):1986-92.
    [6]
    Fernández-Ortega P, Caloto MT, Chirveches E, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life[J]. Support Care Cancer,2012,20(12):3141-8.
    [7]
    Hargreaves R, Ferreira JC, Hughes D, et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting[J]. Ann N Y Acad Sci,2011,1222:40-8.
    [8]
    Vardy J, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy[J].Br J Cancer,2006,94(7):1011-5.
    [9]
    Prommer E.Role of haloperidol in palliative medicine: an update[J].Am J Hosp Palliat Care, 2012,29(4):295-301.
    [10]
    Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam[J].Clin Pharmacokinet,1981,6(2):89-105.
    [11]
    Friedlander ML, Kearsley JH, Sims K, et al.Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy[J]. Aust N Z J Med, 1983,13(1):53-6.
    [12]
    Davies A, Adena MA, Keks NA, et al. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety [J].Clin Ther,1998,20(1):58-71.
    [13]
    Weschules DJ. Tolerability of the compound ABHR in hospice patients[J]. J Palliat Med, 2008,8(6):1135-43.
    [14]
    Moon RB. ABHR gel in the treatment of nausea and vomiting in the hospice patient[J]. Int J Pharm Compounding,2006,10:95-9.
    [15]
    Bleicher J, Bhaskara A, Huyck T, et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy- induced nausea/vomiting: results of two pilot trials[J].J Support Oncol,2008,6(1):27-32.

Catalog

    Article views (1936) PDF downloads (470) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return